Amgen is adding Dark Blue to its tapestry, embedding the U.K. biotech’s preclinical blood cancer program into its ...

Amgen has bought cancer biotech Dark Blue Therapeutics in a deal that could be worth as much as $840mn, marking the latest ...

The deal hands Amgen a drug that destroys two proteins known to drive certain types of acute myeloid leukemia, a profile that ...

Amgen (NASDAQ: AMGN) today announced its acquisition of Dark Blue Therapeutics Ltd., a privately held biotechnology company based in the United Kingdom advancing first-in-class, small ...

Dark Blue Therapeutics ("Dark Blue"), a discovery and development biotech company pioneering the next generation of precision oncology medicines, has been acquired by Amgen (NASDAQ: AMGN).

Amgen is committed to reducing drug costs, expanding its AmgenNow program, and investing in US manufacturing to gain tariff ...

US biotech major Amgen has announced its acquisition of privately-held UK firm Dark Blue Therapeutics, a biotech advancing ...

In what is thought to be the first major pharma M&A deal of the year, Amgen has bought Oxford, UK-based biotech Dark Blue ...

Bristol Myers Squibb BMY and Amgen AMGN are among the largest global biotechnology companies with broad and diverse ...

A phase 3 study of Zenas BioPharma's autoimmune disease candidate has hit its primary endpoint. But, with the result falling ...

Sagebrush Health Services, a nonprofit healthcare provider, has sued Thousand Oaks-based biotech giant Amgen for $7 million in damages in a dispute involving a federal drug discount program. Under the ...

Amgen (AMGN) closed the most recent trading day at $320.71, moving -2.12% from the previous trading session. This change lagged the S&P 500's 0.64% gain on the day. Elsewhere, the Dow gained 1.23%, ...